A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

Greater risk of severe asthma attacks was seen with higher blood ... The findings support incorporation of both blood eosinophils and FeNO into clinical risk stratification, the group concluded.

Physicians and patient advocates are sounding the alarm after the NIH abruptly withdrew a grant renewal application for the ...

a downstream IL-13-derived molecule that is usually associated with eosinophilic inflammation, airway remodelling, and severe airflow obstruction, Al-Ahmad and Ali suggested. Couillard's study ...

those with an eosinophilic count equal to or greater than 300 cells per microlitre. Another key biologic on the horizon is ...

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic ...

Asthma occurred for the first time with the ... a "photographic negative" of the shadows seen in pulmonary edema. Chronic eosinophilic pneumonia was recognized from the consistent pathological ...

Blood eosinophil count and fractional exhaled nitric oxide significantly enhance prognostic assessment of asthma attack risk.

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

The IL-5 inhibitor is already available under the Fasenra brand name for maintenance use in severe eosinophilic asthma, but a new study conducted by researchers at King's College London (KCL ...

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.